Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical terbinafine (AP4500) in mild to moderate toenail onychomycosis
NCT07382427Phase 2Not yet recruiting
- Sponsor
- Onyx Axiom
- Start
- Mar 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of AP4500 in onychomycosis (5 arms), sponsored by Onyx Axiom. Primary endpoint: Complete Cure at 52 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
AP4500
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT07382427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07382427.